Categories AlphaGraphs, Earnings, Health Care
Key highlights from Biogen’s (BIIB) Q1 2022 earnings results
Biogen Inc. (NASDAQ: BIIB) reported first quarter 2022 earnings results today.
Total revenue decreased 6% year-over-year to $2.53 billion.
GAAP net income attributable to Biogen Inc. was $304 million, or $2.06 per share, compared to $410 million, or $2.69 per share, last year. Adjusted EPS amounted to $3.62.
For full-year 2022, total revenue is estimated to be $9.7-10 billion while adjusted EPS is expected to be $14.25-16.00.
Prior performance
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
